Psoriasis Recruiting Phase 3 Trials for Apremilast (DB05676)

Also known as: Psoriasis unspecified / Psoriasis, unspecified

DBCOND0013339 (Psoriasis)Recruiting3 IdentifierTitlePurposeDrugs
NCT03701763Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque PsoriasisTreatment
NCT03777436An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital PsoriasisTreatment
NCT03721172Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and EfficacyTreatment